RAPT Therapeutics, Inc. Banner Image

RAPT Therapeutics, Inc.

  • Ticker RAPT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
RAPT Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate theMore critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.
4.8 / 5.0 (224)

RAPT Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 224 reviews.

RAPT Therapeutics, Inc.

Most Recent Annual Report

RAPT Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

RAPT Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!